Bank of America trimmed Bristol Myers Squibb’s target price from $63 to $58 while sticking with its neutral rating. This reflects lowered revenue and EPS expectations for the company in both the near ...

BofA lowered the firm’s price target on Bristol Myers (BMY) to $58 from $63 and keeps a Neutral rating on the shares. For Q1, the firm’s total ...

Bristol Myers Squibb's stock dipped 1.35% to $49.33, outpacing the broader market’s even grimmer mood. The biopharma giant ...

We recently published a list of 10 Dirt Cheap Stocks To Invest In Now. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other dirt cheap ...

This was the stock's second consecutive day of losses.

Pharma companies are leveraging the United States’ threat of tariffs on drug imports to push for policy changes in the EU. | ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY – Research Report) and ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for ...

The New Jersey-based company's shares fell 1.6% in extended trading. The drug, mavacamten, was tested in adult patients with ...

Mural Oncology plc said on Tuesday it would stop clinical development of its lead cancer treatment, nemvaleukin, and look ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...